Umbralisib: First Approval

Dhillon, S; Keam, SJ

Keam, SJ (corresponding author), Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.

DRUGS, 2021; 81 (7): 857

Abstract

Umbralisib (UKONIQ (TM)) is an oral, first-in-class dual phosphatidylinositol 3-kinase delta (PI3K delta) and casein kinase 1 epsilon (CK1 epsilon) in......

Full Text Link